Insider Activity Highlights
On February 20, 2026, Chief Financial Officer Smith Diron added nearly 1,600 shares of Integer Holdings Corp. through the vesting of performance‑based restricted stock units (PSUs). The transaction is part of a multi‑year incentive plan tied to organic sales growth and shareholder return targets. The shares were delivered at the prevailing market price of $87.10, a modest 0.02 % uptick from the close.
Implications for Investors
The vesting of PSUs signals that the company has met its 2023‑2025 growth and return benchmarks. For shareholders, this is a positive cue that the management team is delivering on the metrics that ultimately drive the stock. Moreover, the fact that the CFO’s shares are coming from a performance‑based pool rather than a direct purchase at a discount reduces dilution concerns. The concurrent sell of 394 shares at $84.85, a few days earlier, suggests a modest liquidity event but is outweighed by the net increase in Diron’s holdings.
Company‑Wide Insider Trends
Across the board, the CEO and several other executives executed a total of 32 buys and 22 sells during the same week. The CEO’s purchases were the largest, with over 40,000 shares added, reinforcing a bullish stance on the company’s trajectory. The CFO’s activity, while smaller in dollar terms, aligns with the broader pattern of executive confidence, especially given the high social‑media sentiment (+94) and buzz (726 % above average). Such elevated chatter can amplify market perception and potentially lift the share price.
Profile of Smith Diron
Diron’s insider history shows a balanced approach: he has frequently sold common stock—often at market price—to fund other opportunities, but he has also acquired significant blocks through restricted stock units and direct purchases. His net position rose from roughly 7,700 shares in November 2025 to 11,760 shares by February 2026, a 53 % increase in a few months. The pattern of buying PSUs that vest only when performance targets are met suggests a long‑term alignment with shareholder value. For investors, Diron’s consistent engagement implies a commitment to the company’s growth plan and a willingness to be rewarded alongside the market.
What It Means for the Future
The recent insider activity, coupled with a robust earnings beat and a stable P/E of 28.7, positions Integer Holdings as a solid play in the medical‑device space. The CFO’s continued stake in the company signals confidence in future profitability, while the broader executive buys reinforce a bullish outlook. For investors, the combination of performance‑based vesting, healthy market sentiment, and strong fundamentals indicates that Integer is poised for incremental upside, provided it continues to meet its operational and financial targets.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-02-20 | Smith Diron (EVP, Chief Financial Officer) | Buy | 798.00 | N/A | Common Stock |
| 2026-02-20 | Smith Diron (EVP, Chief Financial Officer) | Buy | 817.00 | N/A | Common Stock |
| 2026-02-20 | Smith Diron (EVP, Chief Financial Officer) | Sell | 394.00 | 84.85 | Common Stock |
| 2026-02-20 | Khales Payman (President & CEO) | Buy | 7,389.00 | N/A | Common Stock |
| 2026-02-20 | Khales Payman (President & CEO) | Buy | 7,516.00 | N/A | Common Stock |
| 2026-02-20 | Khales Payman (President & CEO) | Sell | 4,638.00 | 84.85 | Common Stock |
| 2026-02-24 | Khales Payman (President & CEO) | Buy | 16,077.00 | 0.00 | Common Stock |
| 2026-02-24 | Khales Payman (President & CEO) | Buy | 26,983.00 | 0.00 | Common Stock |
| 2026-02-24 | Khales Payman (President & CEO) | Sell | 16,945.00 | 87.10 | Common Stock |
| 2026-02-24 | Khales Payman (President & CEO) | Sell | 16,077.00 | N/A | Restricted Stock Units |
| 2026-02-24 | Khales Payman (President & CEO) | Sell | 26,983.00 | N/A | Restricted Stock Units |
| 2026-02-20 | Senn Andrew (President, Cardio & Vascular) | Buy | 2,340.00 | N/A | Common Stock |
| 2026-02-20 | Senn Andrew (President, Cardio & Vascular) | Buy | 2,380.00 | N/A | Common Stock |
| 2026-02-20 | Senn Andrew (President, Cardio & Vascular) | Sell | 1,447.00 | 84.85 | Common Stock |
| 2026-02-20 | Thor Kirk K (Chief Human Resources Officer) | Buy | 4,475.00 | N/A | Common Stock |
| 2026-02-20 | Thor Kirk K (Chief Human Resources Officer) | Buy | 4,550.00 | N/A | Common Stock |
| 2026-02-20 | Thor Kirk K (Chief Human Resources Officer) | Sell | 2,198.00 | 84.85 | Common Stock |
| 2026-02-20 | Thomas Tommy P (VP, Corporate Controller) | Buy | 923.00 | N/A | Common Stock |
| 2026-02-20 | Thomas Tommy P (VP, Corporate Controller) | Buy | 939.00 | N/A | Common Stock |
| 2026-02-20 | Thomas Tommy P (VP, Corporate Controller) | Sell | 713.00 | 84.85 | Common Stock |
| 2026-02-20 | Stephens Jim (President, CRM & Neuro) | Buy | 2,691.00 | N/A | Common Stock |
| 2026-02-20 | Stephens Jim (President, CRM & Neuro) | Sell | 656.00 | 84.85 | Common Stock |




